Neuroscience Antibodies and Assays Market Top Players and Growth Strategies

-
According to research report the Neuroscience Antibodies and Assays Market is expected to reach USD 4.18 Billion by 2023 from USD 2.57 Billion in 2018, at a CAGR of 10.2%. The growth of this market can be attributed to the rising incidence of neurological diseases, increasing investments in neuroscience research, and growth in the pharmaceutical and biotechnology industries.
Agreements, partnerships, and collaborations accounted for the largest share of the overall growth strategies followed by key players between 2015 and 2018. Some of the companies that adopted this strategy include Cell Signaling Technology (US), Abcam (UK), Rockland Immunochemicals (US), BioLegend (US), Tecan (Switzerland), and Merck KGaA (Germany).
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=129888612
The neuroscience antibodies and assays market is fragmented, with the presence of several large as well as emerging players. In 2017, Thermo Fisher Scientific (US), Abcam (UK), Bio-Rad (US), and Merck KGaA (Germany) were the leading players in the neuroscience antibodies and assays market. Other major players include BioLegend (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), GenScript (China), Rockland Immunochemicals (US), Santa Cruz Biotechnology (US), Siemens (Germany), and Tecan (Switzerland).
Thermo Fisher Scientific (US) is one of the prominent players in the neuroscience antibodies and assays market. This leading position of the company can be attributed to its strong brand recognition and extensive product portfolio in the neuroscience antibodies and assays market. The company has a strong foothold in the market with established brands such as Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. In order to maintain its leading position in the neuroscience antibodies and assays market, the company adopts organic as well as inorganic growth strategies such as expansions and acquisitions. For instance, in August 2017, the company acquired Patheon N.V. (Netherlands). This acquisition helped the company to strengthen its product portfolio and geographical presence in the pharmaceutical and biotechnology sector. Furthermore, in 2017, the company opened its new global headquarters in Massachusetts (US).
Abcam (UK) accounted for the second largest share of the neuroscience antibodies and assays market in 2017. The company offers a broad range of solutions for the neuroscience industry, which include primary antibodies, proteins and peptides, agonists, activators, antagonists and inhibitors, ELISA, matched antibody pairs and multiplex immunoassays, lysates, and cellular & biochemical assays. With its wide geographic presence and high production capacity, the company delivers quality products across the globe. This helped the company to develop new and advanced products and cater to the demand of its customers.
Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=129888612
In order to maintain its position in the neuroscience antibodies and assays market, the company focuses on adopting organic as well as inorganic growth strategies. In this regard, in February 2018, the company launched its CatchPoint SimpleStep ELISA (SSE) kits. Also, in February 2018, the company collaborated with Molecular Devices, with the aim to develop high-sensitivity fluorescent ELISA kits, which are immunoassays used to quantify target proteins in basic research. Such developments helped the company enhance its visibility in the neuroscience antibodies and assays market.

Comments

Post a Comment

Popular posts from this blog

Future of Remote Patient Monitoring Industry: Impact of Remote Patient Monitoring on Healthcare

-
Remote patient monitoring is a type of telemedicine technology that enables healthcare providers to monitor their patients’ health remotely. This technology utilizes remote devices that are placed in the patient’s home or worn by the patient to collect medical data such as vital signs and other medical information.  This medical data is then transmitted to the doctor or healthcare provider to help them make better decisions regarding the patient’s care. RPM can be used to monitor a variety of conditions including chronic diseases, mental health issues, and post-operative care. It can also be used to support elderly individuals and those with disabilities. RPM has the potential to improve patient outcomes and reduce healthcare costs by enabling healthcare providers to monitor their patients’ health more effectively. Benefits of Remote Patient Monitoring 1. Increased Patient Engagement: Remote patient monitoring systems provide patients with a convenient way to stay engaged in thei...
Read more

Strategies Adopted by the Major Players in this Digital PCR Market

-
 According to research report the  Digital PCR Market  is expected to grow from USD 3.47 billion in 2017 to USD 5.31 billion by 2022, at a CAGR of 8.9% during the forecast period. Product Launches: Key Strategy Adopted by the Major Players in this Market New product launches and approvals are the key growth strategies adopted by major players to strengthen their position in the global Digital PCR Market. Moreover, strategies such as partnerships, collaborations, and agreements; as well as mergers and acquisitions were also adopted by several market players to strengthen their market position, expand their R&D capabilities, and geographic presence in the global Digital PCR Market. The key players in the Digital PCR Market include Thermo Fisher Scientific, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), bioMérieux S.A. (France), Fluid...
Read more

Sinus Dilation Devices Market Size And Share Report, 2027

-
The sinus dilation devices market is on track for significant growth in the coming years, projected to reach USD 3.8 billion by 2027, up from USD 2.8 billion in 2022. This represents a compound annual growth rate (CAGR) of 6.6% during the forecast period. The market's expansion is largely driven by the increasing availability of reimbursements and rising cases of chronic sinusitis. However, the market faces challenges due to the availability of non-surgical treatments for chronic sinusitis and a shortage of skilled ENT surgeons. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810 Key Market Drivers Increasing Availability of Reimbursements: The growing availability of reimbursements for sinus dilation procedures is making them more accessible to patients, thereby driving demand for sinus dilation devices. Rising Incidence of Chronic Sinusitis: The prevalence of chronic sinusitis is on the rise globally, leading to an increase in d...
Read more